Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201190 | 1.00 | TACR1 (0.42) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL25090397 | 1.00 | TACR1 (0.42) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL25090398 | 1.00 | TACR1 (0.42) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL25090396 | 1.00 | TACR1 (0.42) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL30201048 | 0.87 | TACR1 (0.43) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL25090209 | 0.87 | TACR1 (0.43) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL29328327 | 0.85 | TACR1 (0.42) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL25090235 | 0.85 | TACR1 (0.44) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL30201213 | 0.85 | TACR1 (0.44) | TACR1JAK2JAK1KMT2AMEN1 | |
| SCHEMBL25090505 | 0.82 | ALDH1A1 (0.45) | TACR1KMT2AMEN1TGFBR1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | TACR1 174/4885JAK2 319/4885JAK1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.